Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Acute bacterial skin and skin structure infections

Acute bacterial skin and skin structure infections

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Acute bacterial skin and skin structure infections

3 trials tracked for Acute bacterial skin and skin structure infections: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 64 citations.

3Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 2
  1. Phase 3 Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections Completed · 64 cited
  2. Phase 4 Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Completed · 15 cited
  3. Phase 3 A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) Completed · 5 cited

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA approves nuzyra for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults
Infectious Disease FDA Approval
FDA approves nuzyra for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults FDA approves nuzyra for treating bacterial infections in adult patients safely
The FDA granted approval for nuzyra to treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections i…
The FDA has approved nuzyra to treat community-acquired bacterial pneumonia and skin infections in adults. This regulatory decision confirms…
FDA May 19, 2026